Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report
Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni—15, 40138 Bologna, Italy
Maria Cecilia Hospital, Cotignola (RA), 48033 Ravenna, Italy
Medical Oncology Department, Bellaria Hospital, Azienda USL of Bologna, Via Altura n.3, 40139 Bologna, Italy
Oncology Unit, Department of Experimental, Diagnostic and Specialty Medicine, Sant’Orsola-Malpighi Hospital, University of Bologna, 40138 Bologna, Italy
Author to whom correspondence should be addressed.
Medicines 2021, 8(1), 5; https://0-doi-org.brum.beds.ac.uk/10.3390/medicines8010005
Received: 8 December 2020 / Revised: 7 January 2021 / Accepted: 8 January 2021 / Published: 11 January 2021
Renal cell carcinoma is a malignant tumor that arises in the kidney parenchyma. For many years, sunitinib has represented the mainstay of medical treatment for metastatic renal cell carcinoma. Herein, we present the case of a 66-year-old woman with metastatic clear cell renal carcinoma undergoing treatment with sunitinib for two years that developed encephalic leukocytoclastic vasculitis, probably due to a paraneoplastic syndrome.